stockrow
Saturday 7 November 2026
Export SXTP’s income statement to Excel — free account
60 Degrees Pharmaceuticals Inc.
SXTP Healthcare Biotechnology
60 Degrees Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 106.8% from fiscal 2024.
- Revenue
- −32.5%
- EPS
- +82.0%
- Free cash flow
- −54.3%
Quarter to June 2026, against a year earlier
0.60
0.32
−34.78%
Follow SXTP
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 3 | 6 | 1 | 0 | 1 | 1 | 1 | (11.2%) | 1 | 2 | 2 | +12.4% | |
| Gross margin, % | — | — | — | — | 72.43 | 86.61 | 15.41 | (87.15) | 43.53 | 44.52 | 43.42 | (27.9) pt | ||||||
| EBT | — | — | — | — | (3) | (4) | (6) | (4) | (8) | (7) | (8) | +19.3% | ||||||
| EBT margin, % | — | — | — | — | (119.53) | (67.04) | (1,208.39) | (1,503.79) | (1,167.72) | (522.91) | (650.62) | (403.4) pt | ||||||
| Net income | — | — | — | — | (3) | (4) | (6) | (4) | (8) | (7) | (8) | +19.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.44 | 1.10 | 51.64 | 15.37 | 5.98 | 2.10 | 0.46 | +36.7% | |||||
| Earnings | — | — | — | — | (0.52) | (0.74) | (626.38) | (237.69) | (74.20) | (11.73) | (6.28) | +86.5% | ||||||
| Cash flow | — | — | — | — | (0.03) | (0.11) | (102.02) | (275.33) | (49.54) | (10.22) | (3.31) | +223.4% | ||||||
| Capex | — | — | — | — | 0.00 | (0.01) | (6.08) | (7.02) | (1.59) | (0.33) | (0.11) | n/m | ||||||
| Free cash flow | — | — | — | — | (0.03) | (0.12) | (108.10) | (282.35) | (51.13) | (10.55) | (3.41) | +225.4% | ||||||
| Book value | — | — | — | — | (3.03) | (3.14) | (2,439.30) | 290.79 | 34.69 | 5.04 | 0.95 | n/m | ||||||
| Shares, m | — | — | — | — | 6 | 6 | 0 | 0 | 0 | 1 | 1 | (35.0%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 25.28 | 25.28 | 25.28 | 23.78 | 4.32 | 0.97 | 1.31 | 17.5 | ||||||
| P/B | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | 28.01 | 28.01 | 28.01 | 20.14 | 1.14 | (0.12) | 1.47 | 17.5 | ||||||
| EV/FCF | — | — | — | — | (10.76) | (10.76) | (10.76) | (1.10) | (0.13) | 0.02 | (0.20) | (5.6) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (1) | (1) | (5) | (6) | (7) | (9) | +110.1% | |||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +25.2% | ||||||
| Free cash flow | — | — | — | — | 0 | (1) | (1) | (5) | (6) | (7) | (9) | +111.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 1 | 1 | (23) | 4 | 4 | 3 | 2 | +24.8% | |||||
| Net debt | — | — | — | — | 19 | 19 | 5 | (2) | (3) | (3) | (1) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | (18) | (18) | (24) | 5 | 4 | 3 | 3 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (212.61) | (459.49) | (82.94) | (117.36) | (132.40) | (194.65) | (132.4) pt | |||||
| ROIC | — | — | — | — | 0.00 | (171.52) | 0.00 | (121.31) | (1,070.52) | (771.42) | (348.64) | (771.4) pt | ||||||
| ROE | — | — | — | — | 0.00 | 23.85 | 29.23 | 25.78 | 148.93 | 124.83 | 115.54 | +124.8 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 2 | 3 | 3 | 3 | — | +14.5% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.26 | 0.08 | 0.23 | 0.47 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
60 Degrees Pharmaceuticals Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GRI GRI Bio, Inc. | $3.4M | — (loss-making) | — (loss-making) | — | n/m | +54.33% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LIPO Lipella Pharmaceuticals Inc. | $3.4M | — (loss-making) | — (loss-making) | −36.44% (below 0%: shrinking) | n/m | −41.79% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| TRAW Traws Pharma, Inc. | $3.4M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −25.51% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PBLA Panbela Therapeutics Inc. | $3.4M | — (loss-making) | — | — | n/m | +66.23% (above 0%: growing) | — | 0.00% | Compare |
| ONCO Onconetix, Inc. | $3.2M | — (loss-making) | — (loss-making) | −83.94% (below 0%: shrinking) | n/m | −36.00% (below 0%: shrinking) | 25.15% | (15,969.59%) | Compare |
| SXTP 60 Degrees Pharmaceuticals Inc. | $3.2M | — (loss-making) | — (loss-making) | −32.48% (below 0%: shrinking) | n/m | −54.33% (below 0%: shrinking) | 27.32% | (1,092.40%) | |
| ADXN Addex Therapeutics Ltd. Sponsored ADR | $3.1M | — (loss-making) | — (loss-making) | −85.95% (below 0%: shrinking) | n/m | −2.73% (below 0%: shrinking) | (2.67%) | 0.00% | Compare |
| ERNA Ernexa Therapeutics Inc. | $3.0M | — (loss-making) | — (loss-making) | −94.12% (below 0%: shrinking) | n/m | −64.10% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MBIO Mustang Bio, Inc. | $3.0M | — (loss-making) | — | — | n/m | +27.78% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $3.3M | — | — | −85.95% | — | −14.12% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 2 July 2026
Ownership
Directors and executive officers, together
1.68%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement